Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
|Slideshows|January 18, 2018
The Finer Points of Treatment Resistance
Author(s)Norman Sussman, MD
When patients endure repeated trials of medications to no avail in the areas of PTSD, panic disorder, bulimia nervosa, and other illnesses, psychiatrists are there.
Advertisement
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
How Best to Manage Treatment-Resistant Depression
3
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
4
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
5